Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP5541 in Advanced Prostate Cancer
NCT07005154Phase 2Recruiting
- Sponsor
- Astellas Pharma
- Start
- Aug 2025
- Primary completion
- May 2032
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of abiraterone decanoate in metastatic castration-resistant prostate cancer (mCRPC), prostate cancer (PCa), sponsored by Astellas Pharma. Started Aug 2025; status: recruiting.
02
Drugs
abiraterone decanoate
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07005154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07005154.